Government downplays threat from drug-resistant bacteria
A DRUG-RESISTANT bacteria dubbed superbug has triggered a debate. A gene—New Delhi metallo-beta lactamase (NDM 1)— transforms some bacteria found in the gut, like Escherichia coli and Klebsiella pneumoniae, into superbugs.
They are resistant to all antibiotics, except tigecycline and colistin, said a study published in the August 11 issue of The Lancet Infectious Diseases.
The study, based on a survey conducted in India, Pakistan and the UK, ended with an advisory to patients in the UK that they should not to opt for surgeries in India. In June, the superbug killed a Belgian patient who underwent treatment in Pakistan. The World Health Organization has endorsed the report. It has asked governments to focus on prevention and control through surveillance for anti-microbial resistance, rational use of antibiotics and preventing sale of antibiotics without prescriptions.
Study motivated: doctors
The study rocked the Indian Parliament on August 12. MPs called it a conspiracy by multinational pharmaceutical firms to discredit India as a healthcare destination. Last year, a study by the Confederation of Indian I n d u s t r y and Mckinsey India had predicted that India could earn US $2.4 billion from 2009 to 2012 through medical tourism. The MPs also accused Karthikeyan N Kumaraswamy of Madras University's microbiology department of conflict of interest. A coauthor of the study, Kumaraswamy travelled to UK courtesy pharma company Wyeth.
"The motive behind the study, sponsored by the European Union, Wyeth and Wellcome Trust, a charity, needs to be investigated. It is an attempt to sabotage India's healthcare industry that provides affordable treatment," said Raman Sardana of Hospital Infection Society of India, an association of doctors. Another doctor with the association said there is no concrete evidence of NDM-1 developing in India. The researchers don't know the extent of the spread and since when the bacteria became prevalent in the environment, he said.
Nakun Jain of Health India, a company providing healthcare trips to India, said the superbug has disturbed patients in the UK, though South American and South African visitors remain unaffected. Hospitals in India that would be hit include the Apollo group and Escorts.
What India needs to do
The superbug is not new. NDM-1 was first discussed at an international conference on antibiotic agents and chemotherapy in Washington in October 2008.
Research groups in Mumbai published independent studies on it in the Journal of Association of Physicians of India in March 2010. The greater concern now is that this resistant gene may have passed on to other strains of bacteria which may result in complete resistance to any type of broad spectrum antibiotic, said a researcher associated with study published in The Lancet Infectious Diseases.
V M Katoch, director general of the Indian Council for Medical Research, said bacteria with resistant gene like NDM-1 are commonly found in the environment. So, stringent infection control measures should be taken, he said. But so far neither the Indian Council for Medical Research nor the health ministry has conducted any surveys on infection control in hospitals.
We are a voice to you; you have been a support to us. Together we build journalism that is independent, credible and fearless. You can further help us by making a donation. This will mean a lot for our ability to bring you news, perspectives and analysis from the ground so that we can make change together.
Comments are moderated and will be published only after the site moderator’s approval. Please use a genuine email ID and provide your name. Selected comments may also be used in the ‘Letters’ section of the Down To Earth print edition.